Bristol-Myers Squibb [CELG.RI] vs NextDecade [NEXT] Detailed Stock Comparison
Bristol-Myers Squibb
NYSE
Loading...
NextDecade
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Bristol-Myers Squibb wins in 9 metrics, NextDecade wins in 3 metrics, with 0 ties. Bristol-Myers Squibb appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Bristol-Myers Squibb | NextDecade | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 0.04 | 57.21 | Bristol-Myers Squibb |
| Price-to-Book Ratio | 0.01 | 9.57 | Bristol-Myers Squibb |
| Debt-to-Equity Ratio | 1.15 | 272.45 | Bristol-Myers Squibb |
| PEG Ratio | 0.00 | -10.99 | NextDecade |
| EV/EBITDA | 1.76 | -49.06 | NextDecade |
| Profit Margin (TTM) | 10.24% | 0.00% | Bristol-Myers Squibb |
| Operating Margin (TTM) | N/A | 0.00% | N/A |
| Return on Equity | 24.56% | -10.83% | Bristol-Myers Squibb |
| Return on Assets (TTM) | 7.61% | -2.09% | Bristol-Myers Squibb |
| Free Cash Flow (TTM) | N/A | $-2.66B | N/A |
| 1-Year Return | -40.00% | 33.73% | NextDecade |
| Price-to-Sales Ratio (TTM) | 0.00 | N/A | N/A |
| Enterprise Value | $50.71B | $8.95B | Bristol-Myers Squibb |
| EV/Revenue Ratio | 0.20 | N/A | N/A |
| Gross Profit Margin (TTM) | -2.50% | N/A | N/A |
| Revenue per Share (TTM) | $13 | $0 | Bristol-Myers Squibb |
| Earnings per Share (Diluted) | $0.71 | $-0.69 | Bristol-Myers Squibb |
| Beta (Stock Volatility) | N/A | 1.08 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Bristol-Myers Squibb vs NextDecade Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | 0.00% | 0.00% | 0.00% | -25.00% | -25.00% | -40.00% |
| NextDecade | -2.29% | -1.94% | 28.92% | 49.60% | 29.37% | 33.73% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | -40.00% | -66.67% | -50.00% | -70.00% | -50.00% | -50.00% |
| NextDecade | 33.73% | 44.16% | 665.52% | 12.12% | 11.33% | 11.33% |
Performance & Financial Health Analysis: Bristol-Myers Squibb vs NextDecade
| Metric | CELG.RI | NEXT |
|---|---|---|
| Market Information | ||
| Market Cap | $614.34M | $2.90B |
| Market Cap Category | Small cap | Mid cap |
| 10 Day Avg. Volume | 12,620 | 2,043,974 |
| 90 Day Avg. Volume | 9,473 | 3,057,151 |
| Last Close | $0.03 | $11.10 |
| 52 Week Range | $0.03 - $0.04 | $4.27 - $12.12 |
| % from 52W High | -14.00% | -8.42% |
| All-Time High | $0.17 (Feb 06, 2023) | $20.00 (Jul 24, 2017) |
| % from All-Time High | -82.35% | -44.50% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.10% | N/A |
| Quarterly Earnings Growth | 0.33% | N/A |
| Financial Health | ||
| Profit Margin (TTM) | 0.10% | 0.00% |
| Operating Margin (TTM) | N/A | 0.00% |
| Return on Equity (TTM) | 0.25% | -0.11% |
| Debt to Equity (MRQ) | 1.15 | 272.45 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $2.74 | $1.16 |
| Cash per Share (MRQ) | N/A | $0.50 |
| Operating Cash Flow (TTM) | $10.97B | $-135,586,000 |
| Levered Free Cash Flow (TTM) | $14.50B | $-2,705,118,976 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | $0.00 | N/A |
Valuation & Enterprise Metrics Analysis: Bristol-Myers Squibb vs NextDecade
| Metric | CELG.RI | NEXT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 0.04 | 57.21 |
| Forward P/E | N/A | -10.99 |
| PEG Ratio | 0.00 | -10.99 |
| Price to Sales (TTM) | 0.00 | N/A |
| Price to Book (MRQ) | 0.01 | 9.57 |
| Market Capitalization | ||
| Market Capitalization | $614.34M | $2.90B |
| Enterprise Value | $50.71B | $8.95B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.20 | N/A |
| Enterprise to EBITDA | 1.76 | -49.06 |
| Risk & Other Metrics | ||
| Beta | N/A | 1.08 |
| Book Value per Share (MRQ) | $2.74 | $1.16 |
Financial Statements Comparison: Bristol-Myers Squibb vs NextDecade
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CELG.RI | NEXT |
|---|---|---|
| Revenue/Sales | N/A | $0 |
| Cost of Goods Sold | N/A | $3.15M |
| Gross Profit | N/A | $-3.15M |
| Research & Development | N/A | $307,000 |
| Operating Income (EBIT) | N/A | $-51.92M |
| EBITDA | N/A | $-64.54M |
| Pre-Tax Income | N/A | $-245.23M |
| Income Tax | N/A | N/A |
| Net Income (Profit) | N/A | $-245.23M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CELG.RI | NEXT |
|---|---|---|
| Cash & Equivalents | N/A | $130.94M |
| Total Current Assets | N/A | $404.79M |
| Total Current Liabilities | N/A | $475.68M |
| Long-Term Debt | N/A | $4.69B |
| Total Shareholders Equity | N/A | $1.72B |
| Retained Earnings | N/A | $-542.33M |
| Property, Plant & Equipment | N/A | $173.16M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CELG.RI | NEXT |
|---|---|---|
| Operating Cash Flow | N/A | $-218.51M |
| Capital Expenditures | N/A | $-769.97M |
| Free Cash Flow | N/A | $-838.80M |
| Debt Repayment | N/A | $0 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CELG.RI | NEXT |
|---|---|---|
| Shares Short | N/A | 11.31M |
| Short Ratio | N/A | 3.36 |
| Short % of Float | N/A | 0.07% |
| Average Daily Volume (10 Day) | 12,620 | 2,043,974 |
| Average Daily Volume (90 Day) | 9,473 | 3,057,151 |
| Shares Outstanding | 20.41B | 260.29M |
| Float Shares | N/A | 136.09M |
| % Held by Insiders | N/A | 0.25% |
| % Held by Institutions | N/A | 0.49% |
Dividend Analysis & Yield Comparison: Bristol-Myers Squibb vs NextDecade
| Metric | CELG.RI | NEXT |
|---|---|---|
| Last 12-Month Dividend | $0.00 | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | $0.01 | N/A |
| 3-Year Avg Dividend Yield | 50.00% | N/A |
| 3-Year Total Dividends | $0.04 | N/A |
| Ex-Dividend Date | Oct 04, 2022 | N/A |